Clinical pregnancy rate per woman Participants with BMI < 30 kg/m2 or ≤ 32 kg/m2a · women with polycystic ovary syndrome
It is very uncertain whether metformin changes clinical pregnancy rate per woman Participants with BMI < 30 kg/m2… compared with clomiphene citrate (very low certainty).
Clinical pregnancy rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
It is very uncertain whether metformin changes clinical pregnancy rate per woman Participants with BMI ≥ 30 kg/m2a compared with clomiphene citrate (very low certainty).
Menstrual frequency per woman · women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ovulation rate per woman fParticipants with BMI < 30 kg/m2 · women with polycystic ovary syndrome
Metformin showed no clear difference in ovulation rate per woman Participants with BMI < 30 kg/m2b compared with clomiphene citrate (low certainty).
Gastrointestinal adverse events · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Ovulation rate per woman fParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
Metformin may leads to lower ovulation rate per woman Participants with BMI ≥ 30 kg/m2b compared with clomiphene citrate (low certainty).
Miscarriage · women with polycystic ovary syndrome
It is very uncertain whether metformin changes miscarriage rate per woman compared with clomiphene citrate (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher clinical pregnancy rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Menstrual frequency per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin may leads to higher menstrual frequency per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ovulation rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher ovulation rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Miscarriage · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Live birth rate per woman · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate showed no clear difference in live birth rate per woman compared with clomiphene citrate alone (low certainty).
Gastrointestinal adverse events · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher adverse events (gastrointestinal) per woman compared with clomiphene citrate alone (moderate certainty).
Clinical pregnancy rate · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher clinical pregnancy rate per woman compared with clomiphene citrate alone (moderate certainty).